Research and Policy CSR News

"I Have Never Seen a Moment So Rich in Collaboration, Ingenuity and Acts of Bravery": Johnson & Johnson Announces It Has Identified a Lead Covid-19 Vaccine Candidate

Chairman & CEO Alex Gorsky shares that the company could have the first batches of a Covid-19 vaccine available for emergency-use authorization in early 2021—a substantially accelerated time frame in comparison to the typical vaccine development process.
Blog

By Alex Gorsky, Chairman & CEO, 

The Covid-19 pandemic is one of the greatest challenges to our society in living memory.

Yet even as we are heartbroken by the lives lost and the strain on our institutions and communities, countless people have been working tirelessly to offer the world a reason to feel pride, inspiration and hope.

Hilton and American Express to Donate Up to 1 Million Rooms to Frontline Medical Professionals During COVID-19 Crisis

Press Release

Hilton (NYSE:HLT) and American Express (NYSE:AXP) today announced that the companies, in partnership with Hilton’s ownership community, will donate up to 1 million hotel room nights across the United States to frontline medical professionals leading the fight against COVID-19.

Beginning next week, Hilton and American Express will make rooms available without charge to doctors, nurses, EMTs, paramedics and other frontline medical staff who need a place to sleep, recharge or isolate from their families through the end of May.

COVID-19 Brings Policy Responses, Risks to Emerging Markets, and Hoarding

Growing policy responses reflect greater estimates of the costs of COVID-19.
Summary: 

By Carl R. Tannenbaum, Ryan James Boyle, Vaibhav Tandon

SUMMARY

  • Policy Expands to Counter Economic Contraction

  • Emerging Markets Are Under Rising Pressure

  • The Rationale Behind Hoarding
Article

By Carl R. Tannenbaum, Ryan James Boyle, Vaibhav Tandon

SUMMARY

  • Policy Expands to Counter Economic Contraction

  • Emerging Markets Are Under Rising Pressure

  • The Rationale Behind Hoarding

Keys to Accelerating Your COVID-19 Drug Campaign

As SARS-CoV-2 moves fast through our global population, the pharmaceutical industry faces tremendous pressure to move even faster.
Press Release

March, 2020 - /3BL Media/ - Industry leaders are jousting with questions of how to quickly evaluate new and repurposed drugs while simultaneously readying their operations for rapid transformation. Novel partnerships between private R&D teams and public health agencies are emerging to address the “discovery” half of that equation, which leaves company leaders to grapple with the other half: how can they prepare their operations for commercial-scale manufacturing of a therapy that hasn’t yet been identified or approved? 

The 2020 Call for Code Global Challenge Takes On COVID-19

By Willie Tejada
Article

Nearly one month ago, together with Creator David Clark Cause and in partnership with United Nations Human Rights and the Linux Foundation, we announced climate change as the theme for the 2020 Call for Code Global Challenge. In that brief period, much has changed. COVID-19 (Coronavirus) has spread across the world with unprecedented effect and now has the potential to become the greatest crisis of modern times.

IBM Helps Bring Supercomputers Into the Global Fight Against COVID-19

By Dario Gil, Director of IBM Research
Article

At IBM, I have the privilege of working with colleagues who have dedicated their lives and careers to advancing science and creating innovative technology that can be a force for progress in the world. Since the start of the COVID-19 pandemic we have been working closely with governments in the U.S.

International Research Partnership and EDCTP to Invest €44m in Next-generation Antimalarials to Combat Drug-resistant Malaria in Africa

Summary: 
  • EDCTP grants the PAMAfrica research consortium €21.9 million over a 5 year period; MMV, Novartis and other partners will provide an additional €22 million.
     
  • The PAMAfrica consortium brings together a global medicines company, a not-for-profit product development partnership and leading academic institutions in Africa and Europe. PAMAfrica aims to develop new medicines for both severe and uncomplicated malaria, designed to combat emerging artemisinin resistance.
     
  • The projects will include development of the first new malaria treatment for babies under 5 kg, a new fast-acting medicine for the treatment of severe malaria, and new combinations to treat drug-resistant uncomplicated malaria.
Press Release
  • EDCTP grants the PAMAfrica research consortium €21.9 million over a 5 year period; MMV, Novartis and other partners will provide an additional €22 million.
     
  • The PAMAfrica consortium brings together a global medicines company, a not-for-profit product development partnership and leading academic institutions in Africa and Europe. PAMAfrica aims to develop new medicines for both severe and uncomplicated malaria, designed to combat emerging artemisinin resistance.
     
  • The projects will include development of the first new malaria treatment for babies under 5 kg, a new fast-acting medicine for the treatment of severe malaria, and new combinations to treat drug-resistant uncomplicated malaria.

4 Questions for a Scientist Working on a Revolutionary CAR-T Therapy for Multiple Myeloma

By Jessica Brown
Article

The early data results seemed almost too good to be true.

That's what Sen Zhuang, M.D., Ph.D.,  Vice President, Oncology Clinical Research, Janssen Research & Development, was thinking at a meeting of the American Society of Clinical Oncology (ASCO) last summer.

An Expert Explains the Latest Good—Yes, Good!—News About Lung Cancer

By Jennifer Rainey Marquez
Summary: 

A new report from the American Cancer Society sheds light on declining death rates from cancer—especially lung cancer. We asked an expert on the disease to break down the data, and share what's to come in better detecting and preventing it.

Article

A new report from the American Cancer Society sheds light on declining death rates from cancer—especially lung cancer. We asked an expert on the disease to break down the data, and share what's to come in better detecting and preventing it.

Renewing Efforts to Educate New Communities in the Fight Against HIV

By Douglas Brooks, Executive Director, Community Engagement at Gilead
Blog

Every now and then, I allow myself to revisit a time when I feared hearing the phone ring. That such an ordinary occurrence could induce deep emotion reflected the environment in which many of us resided. Knowing that the call could easily be the news of another friend having died or having been rushed to the hospital sometimes froze me in place.

Pages

Subscribe to Research and Policy